O Shaughnessy Asset Management LLC Purchases 4,569 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

O Shaughnessy Asset Management LLC lifted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 24.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,235 shares of the medical equipment provider’s stock after purchasing an additional 4,569 shares during the period. O Shaughnessy Asset Management LLC’s holdings in Zimmer Biomet were worth $3,067,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the company. Covestor Ltd lifted its position in shares of Zimmer Biomet by 74.1% during the first quarter. Covestor Ltd now owns 1,358 shares of the medical equipment provider’s stock valued at $179,000 after purchasing an additional 578 shares in the last quarter. Ironwood Investment Counsel LLC bought a new stake in Zimmer Biomet in the first quarter worth about $212,000. Intech Investment Management LLC raised its position in Zimmer Biomet by 22.3% in the first quarter. Intech Investment Management LLC now owns 2,177 shares of the medical equipment provider’s stock worth $287,000 after acquiring an additional 397 shares during the period. Nicolet Advisory Services LLC raised its position in Zimmer Biomet by 5.9% in the first quarter. Nicolet Advisory Services LLC now owns 3,430 shares of the medical equipment provider’s stock worth $444,000 after acquiring an additional 191 shares during the period. Finally, M&G Plc bought a new stake in Zimmer Biomet in the first quarter worth about $7,397,000. 88.89% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ZBH has been the subject of several recent research reports. Citigroup reduced their target price on shares of Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. Barclays reduced their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating for the company in a research note on Friday, May 31st. Argus upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 target price for the company in a research note on Tuesday, May 21st. Morgan Stanley reduced their target price on shares of Zimmer Biomet from $130.00 to $120.00 and set an “equal weight” rating for the company in a research note on Monday, July 15th. Finally, Truist Financial reduced their target price on shares of Zimmer Biomet from $130.00 to $117.00 and set a “hold” rating for the company in a research note on Tuesday, July 16th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $129.53.

Zimmer Biomet Price Performance

ZBH stock traded up $0.55 during midday trading on Wednesday, reaching $110.55. The company had a trading volume of 923,810 shares, compared to its average volume of 1,494,045. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.66 and a quick ratio of 0.80. Zimmer Biomet Holdings, Inc. has a 1 year low of $102.00 and a 1 year high of $142.54. The company has a market capitalization of $22.74 billion, a P/E ratio of 23.81, a P/E/G ratio of 1.99 and a beta of 1.01. The firm has a 50-day moving average price of $111.04 and a 200-day moving average price of $119.75.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.07. The firm had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The business’s quarterly revenue was up 3.2% on a year-over-year basis. During the same period in the previous year, the business posted $1.89 EPS. On average, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Wednesday, June 26th will be issued a $0.24 dividend. The ex-dividend date is Wednesday, June 26th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. Zimmer Biomet’s payout ratio is 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.